News
SHJBF
3.000
NaN%
--
Junshi’s TUOYI Gains NRDL Coverage for New Urothelial Cancer Indication
TipRanks · 4d ago
Shanghai Junshi Biosciences Co., Ltd. Class H (1877) Gets a Buy from CICC
TipRanks · 11/05 05:05
Junshi Biosciences Tightens Cash Management of Idle Fundraising Proceeds
TipRanks · 10/29 14:14
Junshi Biosciences Publishes PRC-Standard Q3 2026 Financials for Cross-Market Investors
TipRanks · 10/29 13:37
Junshi Wins Full China Approval for Toripalimab in Advanced Urothelial Cancer
TipRanks · 10/28 14:08
Junshi Biosciences’ Subcutaneous Toripalimab Application Accepted for HER2-Positive Urothelial Cancer
TipRanks · 10/28 14:07
Junshi Biosciences Starts Phase III Trial of Bispecific Antibody JS203 in Aggressive Lymphoma
TipRanks · 10/23 13:11
Junshi Biosciences Sets Board Meeting to Approve Nine-Month Unaudited Results
TipRanks · 10/15 09:08
Junshi Biosciences Grants Reserved A Share Options Under 2025 Incentive Scheme
TipRanks · 09/23 13:41
Shanghai Junshi Biosciences Board Confirms Option Plan Milestone and Cancels Some Options
TipRanks · 09/23 13:08
Shanghai Junshi Biosciences Sets Date for 2026 Interim Results Investor Briefing
TipRanks · 09/04 13:11
UBS Remains a Buy on Shanghai Junshi Biosciences Co., Ltd. Class H (1877)
TipRanks · 09/03 13:05
Junshi Biosciences Discloses Planned Stake Reduction by Key A-Share Investor
TipRanks · 08/31 00:07
SDIC Securities Remains a Buy on Shanghai Junshi Biosciences Co., Ltd. Class H (1877)
TipRanks · 08/29 05:16
Shanghai Junshi Biosciences Co., Ltd. Class H (1877) Gets a Buy from UBS
TipRanks · 08/28 00:36
Junshi Biosciences Board Approves 2026 Interim Report at Fully Attended Meeting
TipRanks · 08/26 13:11
Shanghai Junshi Biosciences Ends 2026 Employee Stock Ownership Scheme
TipRanks · 08/26 10:37
Shanghai Junshi Biosciences Boosts Revenue, Returns to Profit on TUOYI Growth and Strong Financing
TipRanks · 08/26 09:08
Shanghai Junshi Biosciences Completes RMB0.7 Billion Technology Innovation Bond Issuance
TipRanks · 08/21 12:15
Junshi Biosciences Details Stake Reduction by Key Pre-IPO Shareholder
TipRanks · 08/19 12:16
More
Webull provides a variety of real-time SHJBF stock news. You can receive the latest news about Shanghai Junshi through multiple platforms. This information may help you make smarter investment decisions.
About SHJBF
Shanghai Junshi Biosciences Co Ltd is a China-based company primarily engaged in the discovery, development and commercialisation of innovative drugs. The Company’s products primarily include TUOYI toripalimab, recombinant humanized anti-tumor anti-B-and T-lymphocyte attenuator (BTLA) monoclonal Tifcemalimab, MINDEWEI deuremidevir hydrobromide tablets, JUNMAIKANG adalimumab, JUNSHIDA ongericimab, programmed death-1 (PD-1) monoclonal antibody subcutaneous injection formulation and others. The products are primarily used to treat malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases and infectious diseases. The Company primarily operates its businesses in the domestic and American markets.